Case series:Pirrotinib 400mg, orally, once a day. Until the termination event specified in the program occurs.
Sponsors
The First Affiliated Hospital of Guangxi Medical University, Affiliated Hospital of Youjiang Medical College for Nationalities
Conditions
Breast cancerHER2-positive or mutant solid tumors
Phase 4
Pirrotinib for real-world study of patients with HER2-positive or mutated solid tumors
RecruitingChiCTR2000039663
Start: 2020-11-04Updated: 2021-02-08
A real-world study of postoperative adjuvant treatment of HER2-positive early breast cancer with pyrrotinib maleate tablets
RecruitingChiCTR2100045712
Start: 2021-05-01Updated: 2021-12-06
Multicenter cohort study on efficacy and safety of HER2-positive, node-positive breast cancer following intensive adjuvant or neoadjuvant anti-HER2 therapy with pyrotinib
Active, not recruitingChiCTR2200058746
Start: 2022-05-01Updated: 2024-01-14